GOG 209 study: optimal management of advanced endometrial cancer

Dr David Miller talks to ecancer at the 2012 International Gynaecologic Cancer Society meeting in Vancouver about the GOG 209 study and drug regimens for endometrial cancer.

Standard treatment of endometrial cancer usually involves a surgical treatment, as well as chemotherapy. However, in 20-30 percent of patients, where surgery is not possible, advanced endometrial cancer treatment focuses more on chemotherapy and biological therapies.

The GOG 209 study looked to simplify treatment of advanced endometrial cancer, which consists of the three drug regimen of paclitaxel, doxorubicin and cisplatin. This course offered a clear survival advantage but has high toxicity and does not allow for use with targeted therapies.

In a trial testing carboplatin and paclitaxel, normally used in ovarian cancer, it was discovered that this treatment was as useful as the three drug course, but less toxic. This result now opens the possibility for inclusion of targeted therapy as well.

Filming supported by Amgen